Abstract
Shigellosis or bacillary dysentery is caused by organisms belonging to genus Shigella, divided into four species (S. dysenteriae, S. boydii, S.flexneri and S. sonnei). With the exception of S. sonnei which has a single serotype, each species is divided into several serotypes according to the O-polysaccharide antigen of the cell wall (S. dysenteriae has 12 serotypes, S. flexneri has 6 serotypes, and S. boydii has 18 serotypes). Shigella spp. are invasive organisms that penetrate into the enterocytes of the colon epithelium, escape very quickly from the phagocytic vacuole and multiplicate intracellularly. Although non-motile, shigellae can move on an actin skeleton and spread to adjacent cells. The inflammatory process is usually limited to the lamina propria and does not involve the spread of Shigella deeper, into the submucosa. Pathogenesis in Shigella spp. is associated with a constellation of genes encoded on both the chromosome and a large 140 MDa virulence plasmid. These genes can be divided into two groups: regulatory genes and structural genes. The 140 MDa plasmid encodes for all the genes essential for invasion of Shigella into the epithelium of the colon. Regulatory genes are located on the virulence plasmid or on the chromosome.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ashkenazi S., May-Zahav M., Dinari G., Gabbay U., Zilberman A., and Samra Z. 1993. Recent trends in the epidemiology of Shigella infections. Clin. Infect. Dis. 17:897–899.
Chu C. Y., Liu B., Watson D., Szu S. C., Bryla D., Shiloach J., Schneerson R., and Robbins J. 1992. Preparation, characterization and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga’s bacillus) bound to tetanus toxoid. Infect. Immun. 59:4450–4458.
Cohen D., Green M. S., Block C., Rouach T., and Ofek I. 1988. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J. Infect. Dis. 157:1068–1071.
Cohen D., Green M., Block C., Lowell G., and Ofek I. 1989. Immunoglobulin M., A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J. Clin. Microbiol. 27:162–167.
Cohen D., Green M., Block C., Slepon R., Ambar R., Wasserman S, and Levine M. M. 1991. Reduction of transmission of shigellosis by control of house flies (Musca domestica). Lancet 337:993–997.
Cohen D., Ashkenazi S., Green M. S., Yavzori M., Orr N., Slepon R., Lerman Y, Robin G., Ambar R., Block C., Taylor D. N., Hale T. L., Sadoff J. C., and Wiener M. 1994. Safety and immunogenicity of the oral E. coli K12-S. flexneri 2a vaccine (EcSf2a-2) among Israeli soldiers. Vaccine 12:1436–1442.
DuPont H. L., Levine M. M., Hornick R. B., and Formal S. B. 1989. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 159:1126–1128.
Formal S. B., Hale T. L., Kapfer C., Cogan J. P., Snoy P. J., Chung Y, Wingfield M. E., Elisberg B. L., and Baron L. S. 1984. Oral vaccination of monkeys with an invasive Escherichia coli K12 hybrid expressing Shigella flexneri 2a somatic antigen. Infect. Immun. 46:465–469.
Green M. S., Cohen D., Block C., Rouach T., and Dycian R. 1987. A prospective epidemiologic study of shigellosis. Implications for the new Shigella vaccines. Isr. J. Med. Sci. 23:811–815.
Green M. S., Block C., Cohen D., and Slater P. 1991. Four decades of shigellosis in Israel-the epidemiology of a growing public health problem. Rev. Inf. Dis. 13:248–253.
Herrington D. A., Van De Verg L., Formal S. B., Hale T. L., Tall B. D., Cryz S. J., Tramont E. C., and Levine M. M. 1990. Studies in volunteers to evaluate candidate Shigella vaccines. Further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8:353–357.
Institute of Medicine. Prospects for immunizing against Shigella spp. In: New Vaccine Development: Establishing Priorities; Diseases of Importance in Developing Countries, vol. 2; National Academic Press, Washington, D.C., 1986:329–337.
Kotloff L. K., Herrington D. A., Hale T. L., Newland J. W., Van De Verg L., Cogan J. P., Snoy P. J., Sadoff J. C., Formal S. B., and Levine M. M. 1992. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect. Immun. 60:2218–2224.
Levine M. M., DuPont H. L., Gangarosa E. J., Hornick R. B., Snyder M. J., Libonati J. P., Glaser K., and Formai S. B. 1972. Shigellosis in custodial institutions. II. Clinical immunologic and bacteriologie response of institutionalized children to oral attenuated Shigella vaccines. Am. J. Epidemiol. 966:40–49.
Li A., Karnell A., Huan P. T., Cam P. D., Minh N. B., Tram L. N., et al. 1993. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers. Vaccine 11:180–189.
Lindberg A. A., Karnell A., and Stocker B.A.D. Aromatic-dependent Shigella strains as oral live vaccines. In: Woodrow G. C., Levine M. M. (eds.), New Generation Vaccines. Vaccines against Shigella part II. Marcel Dekker, New York, 1990:677–687.
Newland J. W., Hale T. L., and Formal S. B. 1992. Genotypic and phenotypic characterization of an aroD deletion attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen. Vaccine 10:766–776.
Noriega F. R., Wang J. Y, Losonsky G., Maneval D. R., Hone D. M., and Levine M. M. 1994. Construction and characterization of attenuated AaroA AvirG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect. Immun. 62:5168–5172.
Orr N., Robin G., Lowell G., and Cohen D. 1992. Presence of specific immunoglobulin A secreting cells in peripheral blood following natural infection with Shigella sonnei. J. Clin. Microbiol. 30:2165–2168.
Orr N., Robin G., Cohen D., Arnon R., and Lowell G. H. 1993. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect. Immun. 61:2390–2395.
Robbins J. B., Chu C. Y, and Schneerson R. 1992. Hypothesis for vaccine development: serum IgG LPS antibodies confer protective immunity to non-typhoidal Salmonellae and Shigellae. Clin. Infect. Dis. 15:346–361.
Sanchez J. L., Trofa A. F., Taylor D. N., Kushner R. A., DeFraites R. F., Craig S. C., Rao M. R., Clemens J. D., Svennerholm A., Sadoff J. C., and Holmgren J. 1993. Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers. J. Infect. Dis. 167:1446–1449.
Sansonnetti P. J. and Arondel J. 1989. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 7:443–450.
Smollan G. and Block C. 1992. Development of antimicrobial drug resistance among Shigellas isolated at an Israeli hospital from 1977 through 1990. Publ. Health Rev. 18:319–327.
Taylor D. N., Trofa A. C., Sadoff J., Chu C. Y, Bryla D. A., Shiloach J., Cohen D., Ashkenazi S., Lerman Y, Egan M., Schneerson R., and Robbins J. 1993. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2, Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect. Immun. 61:3678–3687.
Taylor D., Phillip D. F., Zapor M., Trofa A., Van de Verg L., Hartman A., Bendiuk N., Newland J. W., Formal S. B., and Sadoff J. C. 1994. Outpatient studies of the safety and immunogenicity of the auxotrophic Escherichia coli-Shigella flexneri hybrid vaccine candidate EcSf2a-2. Vaccine 12:565–568.
Tramont E. C., Chung R., Berman S., Keren D., Kapfer C., and Formal S. B. 1984. Safety and antigenicity of Typhoid-Shigella sonnei vaccine (Strain 5076-IC). J. Infect. Dis. 149:133–136.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cohen, D. et al. (1996). Clinical Trials of Shigella Vaccines in Israel. In: Cohen, S., Shafferman, A. (eds) Novel Strategies in the Design and Production of Vaccines. Advances in Experimental Medicine and Biology, vol 397. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1382-1_21
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1382-1_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1384-5
Online ISBN: 978-1-4899-1382-1
eBook Packages: Springer Book Archive